Evidence map›Paper›PMID 35014601›Full record

Trial reportGut microbes

Effect of antibiotic pretreatment on bacterial engraftment after Fecal Microbiota Transplant (FMT) in IBS-D.

Prashant Singh, Eric J Alm, John M Kelley, Vivian Cheng, Mark Smith, Zain Kassam, Judy Nee, Johanna Iturrino, Anthony Lembo

3 registry-linked trialsOpen access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Gut microbes. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 58 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 4 pooled it
16.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06427863 nanot yet recruitingnot on this map

Effect of Antibiotic Pretreatment on the Efficacy of WMT in the Treatment of Chronic Constipation in Adults: a Multi-center, Randomized, Placebo-controlled Clinical Study

TypeinterventionalSponsorFaming ZhangRan2024 to 2029Enrolled96ConditionsChronic ConstipationArmsOrnidazole, Placebo
NCT06437041 nanot yet recruitingnot on this map

Effect of Antibiotic Pretreatment on the Efficacy of WMT in the Treatment of Irritable Bowel Syndrome in Adults: a Multi-center, Randomized, Placebo-controlledClinical Study

TypeinterventionalSponsorFaming ZhangRan2024 to 2030Enrolled96ConditionsIrritable Bowel SyndromeArmsOrnidazole, Placebo
NCT07699926 nacompletednot on this map

Efficacy of PosBion® Postbiotic Supplementation in Adults With Irritable Bowel Syndrome

TypeinterventionalSponsorMy Myracle Sdn.BhdRan2026 to 2026Enrolled55ConditionsIBS (Irritable Bowel Syndrome), IBD (Inflammatory Bowel Disease), Gut HealthArmsPostbiotic supplementation
3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 4 syntheses or guidelines pooled it, 105 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Review
  11. Fecal Microbiota Transplantation BeyondJournal of Korean medical science · 2026
    Review
  12. Hesperetin mitigates IBD-associated bone loss viaJournal of orthopaedic translation · 2026
    Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Frontiers in microbiology · 2026
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Prashant SinghDivision of Gastroenterology, Department of Medicine, University of Michigan, Ann, Arbor, Michigan.
Eric J AlmCenter for Microbiome Informatics and Therapeutics, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0001-8294-9364
John M KelleyDepartment of Psychology, Endicott College, Beverly, MA, USA.
Vivian ChengDivision of Gastroenterology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
Mark SmithFinch Therapeutics, Somerville, MA, USA.
Zain KassamFinch Therapeutics, Somerville, MA, USA.
Judy NeeDivision of Gastroenterology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
Johanna IturrinoDivision of Gastroenterology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
Anthony LemboDivision of Gastroenterology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
Beth Israel Deaconess Medical Center · USFinch Therapeutics (United States) · USHarvard University · USMassachusetts Institute of Technology · USUniversity of Michigan · US

Funding

Role of FODMAPs in the pathophysiology of diarrhea-predominant Irritable bowel syndromeK23DK129327 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SINGH, PRASHANT · 2021 to 2025
$982k
NIDDK NIH HHS K23 DK129327
6 · The paper itself

Abstract

Fecal microbiota transplantation (FMT) is an attractive strategy to correct microbial dysbiosis in diarrhea-predominant irritable bowel syndrome (IBS-D). Although the mechanism of FMT is thought to be bacterial engraftment, the best approach to achieve engraftment after FMT in IBS-D (and other diseases) is not clear. We evaluated the effect of FMT (with or without pretreatment with antibiotics) on gut microbiome and symptoms in patients with IBS-D. In this randomized, placebo-controlled, single-center study, 44 patients with IBS-D with a least moderate severity (IBS severity scoring system, i.e., IBS-SSS, ≥175) were randomly assigned to one of four groups: single-dose oral FMT alone, single-dose oral FMT following a 7-day pretreatment course of Ciprofloxacin and Metronidazole (CM-FMT) or Rifaximin (R-FMT), or Placebo FMT. Primary endpoint was engraftment post-FMT and secondary endpoints were changes in IBS-SSS, and IBS-quality of life (IBS-QOL) at week 10. Median engraftment was significantly different among the three FMT groups (

Indexed as

Fecal Microbiota TransplantationAdultAnti-Bacterial AgentsBacteriaCiprofloxacinCombined Modality TherapyFecesFemaleGastrointestinal MicrobiomeHumansIrritable Bowel SyndromeMaleMetronidazoleMiddle AgedQuality of LifeRifaximinAnti-Bacterial AgentsCiprofloxacinMetronidazoleRifaximindysbiosisfecal microbiota transferfecal therapyMicrobiome

Identifiers

PMID35014601
PMCPMC8757476
OpenAlexW4205839480

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.